Please login to the form below

Not currently logged in


This page shows the latest ibrutinib news and features for those working in and with pharma, biotech and healthcare.

China’s BeiGene raises $903m from Hong Kong IPO

China’s BeiGene raises $903m from Hong Kong IPO

If approved, it would compete with Johnson &Johnson/AbbVie's big-selling Imbruvica (ibrutinib) and other therapies nearing the market, including AstraZeneca's already-filed acalabrutinib.

Latest news

More from news
Approximately 17 fully matching, plus 66 partially matching documents found.

Latest Intelligence

  • Taking a strategic approach Taking a strategic approach

    In the case of blood cancer drug Imbruvica (ibrutinib) - a key new product for the company - Janssen has requested its single technology appraisal for CLL and MCL be rescheduled to start

  • Pharma deals during November 2014 Pharma deals during November 2014

    Whatever CAR-T's promise, for the time being of course the chronic lymphocytic leukaemia company to beat is Pharmacyclics with Imbruvic (ibrutinib), its oral small molecule still proving remarkably resilient ... Ibrutinib blocks signals that tell

  • Pharma deals during October 2014 Pharma deals during October 2014

    This clinical trial collaboration will look at a phase 1/2 study for Opdivo in combination with Imbruvica [ibrutinib – an oral Bruton's kinase inhibitor] as a treatment option for

  • Deal Watch table for July 2013 Deal Watch table for July 2013

    Quest Diagnostics / Royalty Pharma. Purchase of royalty rights. Ibrutinib (Bruton's tyrosine kinase inhibitor) for CLL and other B-cell cancers (p3).

  • Pharma deals during July 2013 Pharma deals during July 2013

    However, Royalty Pharma did close a deal this month with presumably a fully cooperative partner, Quest Diagnostics, which had deemed the phase III anticancer drug ibrutinib to be non-core and

More from intelligence
Approximately 0 fully matching, plus 5 partially matching documents found.

Featured jobs

Subscribe to our email news alerts


Add my company
Porterhouse Medical Group

The Porterhouse Medical Group provides market research, insights, and scientific and medical communication services to the pharmaceutical industry across the...

Latest intelligence

Solaris Health looks at the gene therapy revolution
Gene therapies are bringing new hope for many people with diseases caused by genetic disorders...
PM Society Digital Awards – the power of together
Our chief executive, Emma Statham, writes about the value of awards and the power of together....
Seduce anyone in four simple steps
You know the health of the global economy is dependent on our ability to seduce one another – don’t you? And you know that we need to be able to...